Iran Pharmaceuticals and Healthcare Report Q3 2009

Table of Contents

Executive Summary 5
SWOT Analysis 6
Table: Iran Pharmaceuticals And Healthcare Industry SWOT 6
Iran Political SWOT 7
Iran Economic SWOT 7
Iran Business Environment SWOT 8
Business Environment Ranking 9
Table: Middle East And Africa Pharmaceutical Business Environment Ratings Q309 9
Limits Of Potential Returns 10
Risks To Realisation Of Returns 10
Market Summary 12
Registration Of Imports 14
Generic Registration 14
Intellectual Property (IP) Regime 14
Intellectual Property Disputes 15
Counterfeit Medicines 15
Pricing And Reimbursement 16
Recent Pricing And Reimbursement Developments 17
Industry Developments18
Epidemiology 18
HIV/AIDS Situation 19
Table: Iran HIV/AIDS Prevalence 20
Healthcare Sector 20
Primary Care 21
Secondary Care 22
Health Insurance 22
Regional Developments 23
International Healthcare Collaboration 23
Pharmaceutical Industry 24
Pharmaceutical Industry Recent Developments 25
Traditional Herbal Remedies 26
Recent Company Activity 27
Retail Pharmacies 27
Research And Development 28
International Pharmaceutical Collaboration 29
Industry Forecast Scenario 30
Overall Drug Market Forecast 30
Table: Iran - Drug Expenditure Forecasts, 2003-2013 31
Industry Growth Factors 32
Table: Iran - Health Expenditure Forecasts, 2003-2013 33
Macroeconomic Growth Factors 34
Table: Iran - Economic Activity 37
Prescription Drug Market Forecast 38
Table: Iran - Prescription Drug Market Forecast, 2003-2013 (US$mn unless otherwise stated) 39
OTC Drug Market Forecast 40
Table: Iran - OTC Market Data Forecasts, 2003-2013 (US$mn unless otherwise stated) 41
Patented Drug Market Forecast 42
Table: Iran - Patented Market Forecasts, 2003-2013 42
Generic Drug Market Forecast 43
Table: Iran - Generics Market Forecasts, 2003-2013 43
Medical Device Market Forecast 44
Table: Iran - Medical Device Market Forecast, 2006-2013 45
Import/Export Market Forecast 46
Table: Iran - Pharmaceutical Trade Indicators, 2003-2013 (US$mn) 47
Other Healthcare Data Forecasts 48
Table: Iran - Other Health Indicators, 2003-2013 48
Key Risks To BMI' s Forecast Scenario 49
Competitive Landscape50
Company Profiles51
Multinationals 51
Novartis 51
Merck & Co 51
Pfizer 51
GlaxoSmithKline 51
Sanofi-Aventis 51
Indigenous Companies 52
Darou Pakhsh 52
Caspian Tamin Pharmaceutical Company* 54
Pharmieco 56
Pars Darou 57
Zahravi 59
Amin 61
Sina Darou Pharmaceutical Company 62
Exir Pharmaceuticals 64
Country Snapshot: Iran Demographic Data 65
Section 1: Population 65
Table: Demographic Indicators, 2005-2030 65
Table: Rural/Urban Breakdown, 2005-2030 66
Section 2: Education And Healthcare 66
Table: Education, 2002-2005 66
Table: Vital Statistics, 2005-2030 66
Section 3: Labour Market And Spending Power 67
Table: Employment Indicators, 1996-2005 67
Table: Consumer Expenditure, 2000-2012 (US$) 68
Table: Average Annual Manufacturing Wages, 2000-2012 68
BMI Forecast Modelling69
How We Generate Our Pharmaceutical Industry Forecasts 69
Pharmaceutical Business Environment Ratings Methodology 70
Ratings Overview 70
Table: Pharmaceutical Business Environment Indicators 70
Weighting 72
Table: Weighting Of Components 72